Quick-Med Technologies is Developing Next Generation Skin Sanitizer Technology to Provide Long-Lasting Protection from MRSA

Released on: March 12, 2008, 1:57 am

Press Release Author: Natasha A. Sorobey

Industry: Healthcare

Press Release Summary: New Technology Is Being Developed to Help Advance the War
against Community-Acquired Infections.

Press Release Body: Gainesville, Florida, March 11, 2008 -- Quick-Med Technologies
reports that it is developing NimbuDermT, an advanced skin and hand sanitizer
technology that human and lab tests show to be a unique combination of instant and
long-lasting personal antimicrobial protection. This innovation comes at a time when
there's growing concern that many common, everyday surfaces-such as doorknobs,
desks, keyboards, and phones-are contaminated with harmful bacteria, including
potentially deadly methicillin-resistant Staphylococcus aureus, or MRSA, and others
resistant to many of today's antibiotics.

Currently, most hand sanitizers rely on alcohol to disinfect and sanitize the skin.
These products do an excellent job of rapidly cleaning hands and extend hand hygiene
to many situations where washing hands simply isn't practical. However, sanitized
hands are quickly vulnerable to recontamination from touching additional surfaces.
Unlike soap, which has some residual protection, traditional hand sanitizers provide
no ongoing protection as their antimicrobial protection ceases as rapidly as hands
dry and the alcohol-based active ingredient evaporates.

"Quick-Med's NimbuDerm technology has the potential to dramatically change the
hand-hygiene paradigm by combining the immediate disinfection power of an instant
sanitizer with the long-lasting antimicrobial persistence of an advanced bio-active
polymer," declared Dr. Gerald M. Olderman, Vice President of R&D and leader of the
company's scientific team. "With many infections being transferred via hand contact,
we believe NimbuDerm's third-generation technology could bring a new level of
hand-hygiene assurance to consumers and healthcare professionals alike" he observed.

Laboratory tests demonstrate that NimbuDerm's unique antimicrobial polymer
properties will kill more than 99.99% of disease causing germs, including the lethal
strain of MRSA. Human use tests show that NimbuDerm also provides the same high
level of continuing antimicrobial protection for 6 hours after each application
without wearing off or losing its effectiveness. Poor hand hygiene is considered to
be a major contributor to the increase in MRSA infections.

MRSA, which has been identified in hospitals for 4 decades, is now increasingly
found in schools, gymnasiums, and offices, and on common "touch surfaces" such as
keyboards, door knobs, desktops, telephones and shopping cart handles. According to
the Centers for Disease Control and Prevention, in 2005 MRSA was responsible for an
estimated 94,000 life-threatening infections and 18,650 deaths in the United States.
MRSA is becoming increasingly problematic, not only in acute care settings, but
also in long-term care facilities and the community. \"We are on the verge of losing
control of the situation, particularly in the hospitals,\" observed Dr. Chip
Chambers, Chief of Infectious Disease at San Francisco General Hospital in a January
20, 2008 feature article in the San Francisco Chronicle.

The NimbuDerm technology contains no triclosan, the active ingredient found in many
antibacterial soaps and the subject of considerable current controversy. Studies
have shown that large polymers such as NimbuDerm will not generate bacterial
resistance. NimbuDerm technology can be incorporated into various formulations, and
is compatible with common additives such as emollients (to help keep skin soft and
hydrated), therapeutic nutrients, and other active ingredients.

NimbuDerm technology is not yet available commercially. Quick-Med Technologies is
seeking a partner to help bring this important and needed technology to the market
in developing final product formulations, preparing marketing plans, and
importantly, taking the necessary steps to satisfy applicable FDA and other
countries' regulatory requirements.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing
broad-based technologies for the healthcare and consumer markets. The Company\'s two
core product groups under development are (1) NIMBUS, a technology employing
advanced polymers that can be used in a wide range of applications from advanced
wound care to industrial and consumer products; and (2) MultiStatT family of
advanced patented methods and compounds, shown to be effective in key skin care
therapy applications for cosmetic, military, and medical markets. For more
information, see: www.quickmedtech.com.

2008 Quick-Med Technologies, Inc. All rights reserved. NIMBUS and MultiStatT are
trademarks of
Quick-Med Technologies, Inc. All other trademarks are the property of their
respective owners.

Safe Harbor Forward-Looking Statements
Certain statements contained in this press release may be deemed to be
forward-looking statements under federal securities laws, and Quick-Med
Technologies, Inc. intends that such forward looking statements be subject to the
safe harbor created thereby. Quick-Med Technologies, Inc. does not undertake an
obligation to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Press Release Distribution By PressReleasePoint(http://www.pressreleasepoint.com)

Quick-Med Technologies, Inc
Natasha A. Sorobey
Investor & Media Relations
Gainesville, Florida
(888) 835.2211 Ext 107

Web Site: http://www.quickmedtech.com

Contact Details: Quick-Med Technologies, Inc
Natasha A. Sorobey
Investor & Media Relations
Gainesville, Florida
(888) 835.2211 Ext 107

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...